USBC · USBC, Inc.

On March 18, 2026, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted or repriced on October 7, 2025. The exercise price of each repriced option was reduced from $1.10 to $0.37 per share. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

The transactions reported involved the repricing of outstanding stock options to purchase 10,000,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), reflecting the options granted on August 6 and October 7, 2025. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of their respective grant dates and in quarterly installments thereafter over the next three years.

The transactions reported involved the repricing of outstanding stock options to purchase 3,750,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), reflecting the options granted on August 6 and October 7, 2025. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of their respective grant dates and in quarterly installments thereafter over the next three years.

On March 18, 2026, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted or repriced on October 7, 2025. The exercise price of each repriced option was reduced from $1.10 to $0.37 per share. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

The transactions reported involved the repricing of outstanding stock options to purchase 7,140,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On October 7, 2025, the Reporting Person was granted an option to purchase 1,960,000 shares of the Company's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

The transactions reported involved the repricing of outstanding stock options to purchase 4,760,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share.

On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share.

On October 7, 2025, the Reporting Person was granted an option to purchase 5,240,000 shares of the Company's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share.

On October 7, 2025, the Reporting Person was granted an option to purchase 7,860,000 shares of the Issuer's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

The transactions reported involved the repricing of outstanding stock options to purchase 1,790,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On August 6, 2025 (the "Grant Date"), the Reporting Person was granted an option to purchase 7,140,000 shares of the Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On August 6, 2025 (the "Grant Date"), the Reporting Person was awarded 335,000 shares of common stock of the Issuer, 50% of which is fully vested on the Grant Date and the remainder of which (the "restricted shares") will vest in 8 quarterly installments with the first two installments vesting six months after the Grant Date. The restricted shares vest in full in the event of a sale of all or substantially all of the Company's sensor related intellectual property or an involuntary termination of Mr. Erickson's employment.

Includes unvested restricted shares.

On August 6, 2025 (the "Grant Date"), the Reporting Person was granted an option to purchase 1,790,000 shares of the Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On the Grant Date, the Issuer redeemed 16,916 shares of Series H Convertible Preferred Stock held by J3E2A2Z (as defined below) for a combination of cash and common stock at a redemption price equal to the stated value of $70, plus all accrued and unpaid dividends in an amount of $140,210.15, resulting in (i) a cash payment to J3E2A2Z of $654,276.15 in the aggregate and (ii) the issuance to J3E2A2Z of 2,000,000 shares of common stock in the aggregate, at a conversion price of $0.335 per share.

Held by J3E2A2Z Limited Partnership ("J3E2A2Z"), an entity affiliated with Ronald P. Erickson.

On August 6, 2025 (the "Grant Date"), the Reporting Person was granted an option to purchase 4,760,000 shares of the Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.

On the Grant Date, the Issuer redeemed 16,916 shares of Series H Convertible Preferred Stock held by J3E2A2Z (as defined below) for a combination of cash and common stock at a redemption price equal to the stated value of $70, plus all accrued and unpaid dividends in an amount of $140,210.15, resulting in (i) a cash payment to J3E2A2Z of $654,276.15 in the aggregate and (ii) the issuance to J3E2A2Z of 2,000,000 shares of common stock in the aggregate, at a conversion price of $0.335 per share.

Held by J3E2A2Z Limited Partnership ("J3E2A2Z"), an entity affiliated with Ronald P. Erickson.

Shares of Series H Convertible Preferred Stock were issued pursuant to a Promissory Note Conversion Agreement dated 06/02/2025, whereby J3E2A2Z LP, holder of two convertible redeemable promissory notes, converted $1,184,066 in debt owed. J3E2A2Z received one share of Series H Convertible Preferred Stock for every $70 in principal converted. The Series H Convertible Preferred Stock is convertible into common stock at an initial conversion price of $0.335 per share, subject to potential future adjustment.

Held by J3E2A2Z Limited Partnership, an entity affiliated with Ronald P. Erickson.

The option becomes exercisable ratably over a four-year period from the date of grant.

Option shares vest immediately.

Option shares vest immediately.

Option shares vest immediately.

Option shares vest immediately.